Breaking News

EirGenix Licenses Transcenta’s HiCB Platform to Improve Process Efficiency

Combines Transcenta’s continuous biomanufacturing platform and EirGenix’s bioprocessing and CDMO expertise.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Transcenta

Transcenta Therapeutics, a global biopharmaceutical company with capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical development and manufacturing company. Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters